First Phase 3 human trials of Sinopharm's COVID-19 vaccine with inactivated virus begins in Abu Dhabi

The UAE Health Authorities have reportedly issued a permit for up to 15,000 volunteers to take part in the trials.

tech2 News Staff July 20, 2020 12:38:57 IST
First Phase 3 human trials of Sinopharm's COVID-19 vaccine with inactivated virus begins in Abu Dhabi

The first clinical Phase III trials of an inactivated vaccine to combat COVID-19 is underway in the United Arab Emirate capital of Abi Dhabi. The vaccine, developed by Sinopharm China National Biotec Group Company (CNBG), the trial is being carried out in a cooperation partnership between G42 Healthcare, an Abu Dhabi-based organisation leading the UAE's COVID-19 clinical trial efforts.

Abu Dhabi's Chairman of the Department of Health, H E Sheikh Abdullah bin Mohammed Al Hamed, was reportedly the first recipient of the experimental shot, which was the first human trial of a COVID-19 vaccine using inactivated virus. The Department’s Acting Undersecretary Dr Jamal Al Kaabi is said to have followed him as the second volunteer in the trial.

The trials are being carried out by trained health practitioners from the Abu Dhabi Health Services (SEHA). SEHA has reportedly converted five of their sites in Abu Dhabi and neighbouring emirate Al Ain into testing facilities, on top of a mobile clinic to ensure ready access of the experimental vaccine to trial volunteers.

A key concern in clinical trials of global relevance like a COVID-19 vaccine trial, is to study the feasibility of a vaccine is to observe its effects in multiple ethnicities and races. Sinopharm sought after UAE's participation in the Phase 3 trials for the inactivated vaccine since it is home to a diverse range of nationalities.

The UAE Health Authorities have reportedly issued a permit for up to 15,000 volunteers to take part in the trials.

Updated Date:

also read

Rich nations with 13% of world's population secure over half COVID-19 vaccine in late-stage trials, says Oxfam report
World

Rich nations with 13% of world's population secure over half COVID-19 vaccine in late-stage trials, says Oxfam report

At least, 51% of 5.9 billion doses expected to be available for supply post successful trials have been snapped up by the US, Britian, Australia, Japan, Switzerland, Israel, the EU and Hong Kong and Macau, the report claimed

AstraZeneca's COVID-19 vaccine trial paused after 'potentially unexplained' adverse reaction in participant
World

AstraZeneca's COVID-19 vaccine trial paused after 'potentially unexplained' adverse reaction in participant

In a statement issued on Tuesday evening, AstraZeneca said its "standard review process triggered a pause to vaccination to allow review of safety data"

WHO won't endorse COVID-19 vaccine unless it is effective and safe says Tedros Ghebreyesus
World

WHO won't endorse COVID-19 vaccine unless it is effective and safe says Tedros Ghebreyesus

He also said, “The anti-vaccine movement, they can build narratives to fight against vaccines but the track record of vaccines tells its own story and people should not be confused."